The Portfolio Construction and Strategy Team explain why investors should consider a dedicated allocation to healthcare.
Our latest thinking on the themes shaping today’s investment landscape. Explore timely updates, quarterly features and in-depth analysis straight from our experts.
Andy Acker discusses how pricing power, growing demand, and an improving outlook for biotech could bolster the sector heading into 2023.
Why health care could be well positioned to offer both defense against market volatility and opportunities for long-term growth.
The biopharmaceutical industry often moves to the beat of its own drum, creating opportunities for diversification.
What are the opportunities in the healthcare sector in today’s uncertain financial markets?
For more than a year, biotechnology stocks have been deep in the red, even as medical breakthroughs continue – a disconnect we think is unlikely to last.
A new drug targeting a common mutation found in tumors represents a breakthrough in cancer therapy and a potential new source of growth for biopharma.
With Georgia’s Senate run-off vote offering a final, dramatic twist in the US election, what would it mean if Peach State voters hand power to the Democrats? Paul O’Connor, Head of the UK-based Multi Asset Team, considers the ramifications of a potentially seismic political result.